Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftaroline fosamil - AbbVie/Sumitomo Pharma/Takeda

Next Previous
X
Search
Drug Profile

Ceftaroline fosamil - AbbVie/Sumitomo Pharma/Takeda

Alternative Names: Ceftaroline acetate; CX-0903; DSP-5990; PPI-0903; TAK-599; Teflaro; Zinforo

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer AbbVie; Allergan; AstraZeneca; Cerexa; Forest Laboratories; Pfizer; Sumitomo Pharma; Wayne State University
  • Class Antibacterials; Azabicyclo compounds; Cephalosporins; Pyridinium compounds; Small molecules; Thiadiazoles
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Registered Bacteraemia
  • Phase II Sepsis
  • No development reported Bacterial infections
  • Discontinued Osteomyelitis

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 28 Jan 2022 No recent reports of development identified for phase-I development in Bacterial-infections(In adolescents, In children, In infants) in USA (IV, Infusion)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top